American Century Companies Portfolio holdings
American Century Companies, Inc., founded in 1958 by James E. Stowers Jr. as Twentieth Century Mutual Funds and headquartered in Kansas City, Missouri, is a privately held investment management firm renowned for its focus on delivering investment results to clients while supporting medical research. Starting with just $100,000 from 24 shareholders, it rebranded to American Century Investments in 1997 and now manages hundreds of billions in assets across mutual funds, ETFs, and institutional portfolios, emphasizing no-load funds and a client-centric approach. The firm’s unique ownership structure sees over 40% of its profits funneled to the Stowers Institute for Medical Research, which it majority-owns, funding groundbreaking biomedical research, while Nomura Holdings holds a significant minority stake. With a global presence in cities like New York, London, and Hong Kong, and a workforce of around 1,400, American Century blends financial expertise with a mission to improve lives through both wealth creation and scientific advancement.
Top Buys
| 1 |
Becton Dickinson
BDX
|
+$389M |
| 2 |
Meta Platforms (Facebook)
META
|
+$296M |
| 3 |
Salesforce
CRM
|
+$207M |
| 4 |
Howmet Aerospace
HWM
|
+$122M |
| 5 |
Reinsurance Group of America
RGA
|
+$121M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$349M |
| 2 |
Visa
V
|
+$249M |
| 3 |
IQVIA
IQV
|
+$234M |
| 4 |
T-Mobile US
TMUS
|
+$226M |
| 5 |
NXP Semiconductors
NXPI
|
+$212M |
Sector Composition
| 1 | Technology | 23.35% |
| 2 | Healthcare | 13.84% |
| 3 | Financials | 13.36% |
| 4 | Consumer Discretionary | 11.5% |
| 5 | Industrials | 10.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2601
Seer Inc
SEER
$114M
| $111K | ﹤0.01% |
26,066
+10,999
| +73% | +$47K |
|
2602
Medallion Financial
MFIN
$249M
| $111K | ﹤0.01% |
13,982
| – | – |
|
2603
Clarus
CLAR
$154M
| $110K | ﹤0.01% |
+12,060
| New | +$110K |
|
2604
Vuzix
VUZI
$178M
| $109K | ﹤0.01% |
+21,461
| New | +$109K |
|
2605
Five Point Holdings
FPH
$417M
| $108K | ﹤0.01% |
37,448
-492
| -1% | -$1.42K |
|
2606
BioCryst Pharmaceuticals
BCRX
$1.7B
| $105K | ﹤0.01% |
14,899
-51
| -0.3% | -$359 |
|
2607
Broadwind
BWEN
$48.8M
| $102K | ﹤0.01% |
+26,639
| New | +$102K |
|
2608
Kodiak Sciences
KOD
$531M
| $101K | ﹤0.01% |
+14,641
| New | +$101K |
|
2609
Fate Therapeutics
FATE
$113M
| $101K | ﹤0.01% |
+21,214
| New | +$101K |
|
2610
CommScope
COMM
$3.59B
| $101K | ﹤0.01% |
17,888
-43,296
| -71% | -$244K |
|
|
BLUE
2611
DELISTED
bluebird bio
BLUE
| $100K | ﹤0.01% |
1,526
+786
| +106% | +$51.7K |
|
2612
Frontier Group Holdings
ULCC
$1.16B
| $99K | ﹤0.01% |
+10,241
| New | +$99K |
|
2613
eHealth
EHTH
$119M
| $98.2K | ﹤0.01% |
+12,211
| New | +$98.2K |
|
2614
Generation Bio
GBIO
$41.4M
| $97.8K | ﹤0.01% |
1,779
+734
| +70% | +$40.4K |
|
2615
Geron
GERN
$868M
| $96.8K | ﹤0.01% |
+30,164
| New | +$96.8K |
|
2616
Ribbon Communications
RBBN
$717M
| $94.9K | ﹤0.01% |
34,009
+20,505
| +152% | +$57.2K |
|
2617
El Pollo Loco
LOCO
$313M
| $93.8K | ﹤0.01% |
+10,697
| New | +$93.8K |
|
2618
Fulcrum Therapeutics
FULC
$392M
| $93.8K | ﹤0.01% |
28,417
+8,214
| +41% | +$27.1K |
|
2619
Culp
CULP
$57.4M
| $92.9K | ﹤0.01% |
18,699
| – | – |
|
2620
Lands' End
LE
$432M
| $92.8K | ﹤0.01% |
11,954
+1,413
| +13% | +$11K |
|
2621
MannKind Corp
MNKD
$1.69B
| $92K | ﹤0.01% |
22,609
-354
| -2% | -$1.44K |
|
2622
Olema Pharmaceuticals
OLMA
$511M
| $91.6K | ﹤0.01% |
+10,142
| New | +$91.6K |
|
2623
SelectQuote
SLQT
$351M
| $90.4K | ﹤0.01% |
+46,337
| New | +$90.4K |
|
2624
Y-mAbs Therapeutics
YMAB
$390M
| $89.4K | ﹤0.01% |
+13,173
| New | +$89.4K |
|
2625
Nuvation Bio
NUVB
$1.15B
| $89.2K | ﹤0.01% |
49,569
+22,073
| +80% | +$39.7K |
|